These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23725227)

  • 1. Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
    Haire B; Folayan MO; Hankins C; Sugarman J; McCormack S; Ramjee G; Warren M
    Dev World Bioeth; 2013 Aug; 13(2):87-94. PubMed ID: 23725227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
    Haire B; Kaldor J; Jordens CF
    Am J Bioeth; 2012; 12(6):21-30. PubMed ID: 22650457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethics and pre-exposure prophylaxis for HIV infection.
    Sugarman J; Mayer KH
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S135-9. PubMed ID: 23764625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA paves the way for pre-exposure HIV prophylaxis.
    Holmes D
    Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
    [No Abstract]   [Full Text] [Related]  

  • 5. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
    PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
    Gupta RK; Wainberg MA; Brun-Vezinet F; Gatell JM; Albert J; Sönnerborg A; Nachega JB
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S101-6. PubMed ID: 23687287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antiretroviral chemoprophylaxis: current status.
    Baeten J; Celum C
    Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
    Karim SS; Kashuba AD; Werner L; Karim QA
    Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939
    [No Abstract]   [Full Text] [Related]  

  • 13. From modeling to morals: imagining the future of HIV PREP in Lesotho.
    Kenworthy NJ; Bulled N
    Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Baeten JM; Haberer JE; Liu AY; Sista N
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
    Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
    Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
    Denton PW; Krisko JF; Powell DA; Mathias M; Kwak YT; Martinez-Torres F; Zou W; Payne DA; Estes JD; Garcia JV
    PLoS One; 2010 Jan; 5(1):e8829. PubMed ID: 20098623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.
    Nadery S; Geerlings SE
    Neth J Med; 2013; 71(6):295-9. PubMed ID: 23956310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
    Ware NC; Wyatt MA; Haberer JE; Baeten JM; Kintu A; Psaros C; Safren S; Tumwesigye E; Celum CL; Bangsberg DR
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):463-8. PubMed ID: 22267018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.